Testing ivonescimab in people whose glioblastoma has come back
Original title: A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early study that is still working out the right dose in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called ivonescimab in people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has returned.
Who this trial is for. This trial is for people who have recurrent glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, meaning the tumor has come back. It is testing a drug called ivonescimab.
Where it stands. The trial has not reported results. Phase 1 is looking for the highest dose of ivonescimab that people can tolerate, and the dose to use in Phase 2. Phase 2 is looking at whether that dose can help control the disease. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If your glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has come back, this is one study that is looking at a new drug. Someone who fits the description could ask their care team about it. The care team can help sort out whether it makes sense for you.
What it doesn't mean: This does not mean ivonescimab works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.